DISCLOSURE OF UNAPPROVED STATUS OF PRODUCTS DOES NOT PREVENT EXCHANGE OF INFO ON OFF-LABEL USES, FDA MAINTAINS IN REQUEST FOR COMMENTS ON CME POLICY

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".